GUAM 

 

Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 41 24 1 0 42 24 65 1 66
2001

58

32

 1 0 59 32 90 1 91
2002 64 34 1 1 65 35 98 2 100
                   

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 44 47 1 48
2001 19 63 1 64
2002 1 64 1 65
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 35 13 8 2
2001 18 11 1 1
         

 

Pediatric AIDS cases reported

Year
2000 0
2001 0
2002 0
   

 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 60
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 60
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 0

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  GU USA
Men 53 680,909
Women 6 146,298
Total 59 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 3
New Adult/Adolescent AIDS Cases, Reported in 2001 12
New AIDS Cases in Children <13, Reported through December 2001 0

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  GU USA
Men 11 31,901
Women 1 11,082
Total 12 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 35
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 34
Estimated Number of Children Living with AIDS at the End of 2002 1
HIV Infection Cases Reported in 2002 1

 

Total Deaths Reported through 2000, due to AIDS = 29
HIV Reporting Requirements ?   Yes, Name Based.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  N/A
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  N/A
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  N/A
 
Minors' Right to Consent to HIV/STD Services?  N/A

 

 
Total Ryan White Funding, FY2000   $88,809 FY2002  $118,503

 

CDC HIV Prevention Funding for States
 FY2001 $341,759

 FY2003   $541,759

 

Total Federal and State Funding for ADAP, FY2001  $78,468

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.


 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation
 

Total ADAP Clients Served, June 2002  
  GU
#		 US
#
   5 80,035

 
ADAP Clients Served by Sex, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  Male 5 99 62,034 78
  Female 0 1 16,702 21
  Total 5 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  White 0 0 29,426 37
  Black 0 0 26,245 33
  Hispanic 0 0 19,883 25
  Asian/Pacific Islander 5 100 795 1
  American Indian/Alaskan Native 0 0 795 1
  Other 0 0 795 1
  Total 5 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  <13 years old 0 0 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 5 100 50,105 63
  >44 years old 0 0 27,836 35
  Total 5 100 79,531 100

 
ADAP Clients Served by Income, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  <100% FPL 5 100 38,175 48
  101-200% FPL 0 0 26,245 33
  201-300% FPL 0 0 8,748 11
  301-400% FPL 0 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 5 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 0 0 0 6
  Private 0 0 0 13

  
National ADAP Budget, Total Federal and State Sources, FY 2002  
  GU
$		 US
$
   118,503 878,610,754

 
National ADAP Budget by Source, FY 2002  
  GU
$		 GU
%		 US
$		 US
%
  ADAP Earmark 67,389 57 619,830,000 71
  Title II Base 51,114 43 28,886,192 3
  State 0 0 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 118,503 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  GU
$		 US
$
   3,062 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  GU
$		 GU
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors NA  NA  31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors NA  NA  7,940,575 12
  Protease Inhibitors NA  NA  16,433,502 25
  Opportunistic Infections/Other NA  NA  9,015,329 14
  Total 3,062 NA  64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  GU
#		 US
#
   12 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  GU
#		 GU
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors NA  NA  83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors NA NA  23,933 10
  Protease Inhibitors NA  NA  33,813 15
  Opportunistic Infections/Other NA  NA  87,746 38
  Total 12 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  GU
$		 US
$
   NA 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  GU
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 7 NA
  Protease Inhibitors Covered 4 NA
  Non-nucleosides Covered 2 NA
  OI Prophylaxis Covered 6 NA
  Other Medications Covered 7 NA
  Total 26 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  GU
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place Yes 16 Yes
  Notes Capped enrollment.